1,2-二(溴甲基)-4-氯苯 | 31684-14-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,2-二(溴甲基)-4-氯苯
• 中文别名: 1,2-双(溴甲基)-4-氯苯
• 英文名称: 1,2-bis(bromomethyl)-4-chlorobenzene
• CAS: 31684-14-7
• 化学式: C₈H₇Br₂Cl
• 分子量: 298.405
• InChiKey: MUTSJBZAMXKKFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2903999090

反应信息

• 作为反应物：
  描述：

  1,2-二(溴甲基)-4-氯苯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 [(t-BuXPhos)Au]NTf₂ 、 三乙胺 作用下， 以 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 15.0h， 生成 2-benzyl-6-chloro-10-cinnamyl-3a,4,9,9a-tetrahydro-1H-4,9-epiminobenzo[f]isoindole-1,3(2H)-dione
  参考文献：
  名称：

  Gold-Catalyzed [1,5]-Hydride Shift onto Unactivated Alkynes To Trigger an Intermolecular Diels–Alder Reaction

  摘要：

  A [1,5]-hydride shift of sp(3) C-H onto an unactivated carbon carbon triple bond catalyzed by a gold(I) complex enabled N-propargylisoindolines to be latent dienes and therefore triggered an intermolecular Diels-Alder reaction with dienophiles. This protocol provides an atom-economical and straightforward approach to access a wide range of polycyclic skeletons in high yields and with excellent diastereoselectivities from easily accessible molecules.

  DOI：

  10.1021/ol5017355
• 作为产物：
  描述：

  4-氯代苯酐 在 lithium aluminium tetrahydride 、 氢溴酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.5h， 生成 1,2-二(溴甲基)-4-氯苯
  参考文献：
  名称：

  WO2008/151211

  摘要：

  公开号：

文献信息

• COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
  申请人：COGNITION THERAPEUTICS, INC.

  公开号：US20170197977A9

  公开（公告）日：2017-07-13

  This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking change in neuronal cells, and treating cognitive decline and neurodegenerative diseases and disorders therewith.

  这项发明涉及与sigma-2受体结合的新型二芳胺化合物，包括这种化合物的药物组合物，以及用于抑制或恢复神经元细胞中突触丢失，调节神经元细胞中膜运输变化，并用于治疗认知衰退和神经退行性疾病和障碍的方法。
• [EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET PROCÉDÉ D'UTILISATION CORRESPONDANT
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2013119895A1

  公开（公告）日：2013-08-15

  Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供了噻吩化合物，其合成方法，包含这些化合物的药物组合物，以及它们的使用方法。本文提供的化合物可用于治疗、预防和/或管理各种神经系统疾病，包括但不限于精神病和精神分裂症。
• PHARMACEUTICAL COMPOUNDS
  申请人：Congreve Miles Stuart

  公开号：US20100152184A1

  公开（公告）日：2010-06-17

  The invention provides a compound for use in medicine, the compound being a compound of the formula (VI 0 ) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R 1 is hydrogen, hydroxy, or O—R z ; R 2a is hydroxy, methoxy or O—R z ; provided that at least one of R 1 and R 2a is O—R z ; R z is L p -R p1 ; SO 3 H; a glucuronide residue; a mono-, di- or tripeptide residue; or L p is a bond, C═O, (C═O)O, (C═O)NR p1 or S(O) x NR p1 ; x is 1 or 2; R p1 is hydrogen or a an optionally substituted C 1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that R p1 is not hydrogen when L p is a bond, C═O or (C═O)O; and provided also that O—R z does not contain an O—O moiety; and excluding compounds wherein R 1 is hydroxy and R 2a is methoxy; R p2 and R p3 are the same or different and each is a group R p1 ; and R 3 , R 4a , R 8 and R 10 are defined in the claims. The compounds of formula (VI 0 ) are pro-drugs of parent compounds wherein R 1 and/or R 2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.

  本发明提供了一种用于药物中的化合物，该化合物是式(VI0)的化合物或其盐、溶剂化物、互变异构体或N-氧化物：其中双环基团：选自结构C1、C5和C6：其中n为0、1、2或3；R1为氢、羟基或O—Rz；R2a为羟基、甲氧基或O—Rz；条件是R1和R2a中至少一个是O—Rz；Rz为Lp-Rp1；SO3H；一个葡萄糖苷酸残基；一个单、二或三肽残基；或Lp为键、C═O、(C═O)O、(C═O)NRp1或S(O)xNRp1；x为1或2；Rp1为氢或一个可选地取代的含0、1或2个碳环和0、1、2、3、4、5或6个碳-碳多重键的C1-25烃基团，条件是当Lp为键、C═O或(C═O)O时，Rp1不是氢；并且还条件是O—Rz不包含O—O部分；并排除R1为羟基且R2a为甲氧基的化合物；Rp2和Rp3相同或不同，且各自为Rp1基团；R3、R4a、R8和R10如权利要求中定义。式(VI0)的化合物是其中R1和/或R2a为羟基的母化合物的前药，其中母化合物具有Hsp90抑制活性。
• [EN] CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE ATF4
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018225093A1

  公开（公告）日：2018-12-13

  The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (IIIQ): wherein X6', a, b, C8', D8', L82', L83', R81', R82', R83', R84', R85', R86', z82', z84', z85', and z86' are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway. Accordingly, invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及取代的桥环脂环烷衍生物。具体而言，该发明涉及符合以下式（IIIQ）的化合物：其中X6'，a，b，C8'，D8'，L82'，L83'，R81'，R82'，R83'，R84'，R85'，R86'，z82'，z84'，z85'和z86'如本文所定义；或其盐。该发明的化合物是ATF4途径的抑制剂。因此，该发明进一步涉及包括该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包括该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。
• NOVEL SULFONYL DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1104754A1

  公开（公告）日：2001-06-06

  Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

  以下是通用公式（I）所代表的磺酰衍生物：Q1-Q2-T1-Q3-SO2-QA以及含有这些衍生物的药物（其中Q1是可选择地取代的饱和或不饱和的五元或六元环烃基团，五元或六元杂环基团等；Q2是单键，氧，硫，C1-C6烷基或类似物；QA是可选择地取代的芳基烯烃基团，杂环芳基烯烃基团或类似物；T1是羰基或类似物）。这些化合物具有强大的FXa抑制作用，并通过口服迅速产生令人满意且持久的抗血栓作用，因此可作为几乎不伴随副作用的抗凝血剂。